Dr. Mitra's bibliography at NIH.gov
Publications Highlights
Mitra S, Chen B, Shelton JM, Nitschke S, Wu J, Covington L, Dear M, Lynn T, Verma M, Nitschke F, Fuseya Y, Iwai K, Evers BM, Minassian BA. Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses. Acta Neuropathol. 2024 Feb 27;147(1):46. doi: 10.1007/s00401-024-02698-x. PubMed PMID: 38411740.
Mitra S, Chen B, Wang P, Chown EE, Dear M, Guisso DR, Mariam U, Wu J, Gumusgoz E, Minassian BA. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy. Dis Model Mech. 2023 Jan 1;16(1). doi: 10.1242/dmm.049802. Epub 2023 Jan 6. PubMed PMID: 36511140; PubMed Central PMCID: PMC9844227.
Nitschke S, Sullivan MA, Mitra S, Marchioni CR, Lee JPY, Smith BH, Ahonen S, Wu J, Chown EE, Wang P, Petković S, Zhao X, DiGiovanni LF, Perri AM, Israelian L, Grossman TR, Kordasiewicz H, Vilaplana F, Iwai K, Nitschke F, Minassian BA. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency. Brain. 2022 Jul 29;145(7):2361-2377. doi: 10.1093/brain/awac017. PubMed PMID: 35084461; PubMed Central PMCID: PMC9612801.
Aboujaoude A, Minassian B, Mitra S. LUBAC: a new player in polyglucosan body disease. Biochem Soc Trans. 2021 Nov 1;49(5):2443-2454. doi: 10.1042/BST20210838. Review. PubMed PMID: 34709403; PubMed Central PMCID: PMC8589444.
Gumusgoz E, Guisso DR, Kasiri S, Wu J, Dear M, Verhalen B, Nitschke S, Mitra S, Nitschke F, Minassian BA. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models. Neurotherapeutics. 2021 Apr;18(2):1414-1425. doi: 10.1007/s13311-021-01040-7. Epub 2021 Apr 8. PubMed PMID: 33830476; PubMed Central PMCID: PMC8423949.